Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression - Apolo, A B; Infante, J R; Hamid, O (J Clin Oncol, 2016)
(suppl abstr 4514)